The biosimilar, Zarxio (filgrastim-sndz, Sandoz), is now available in the United States. 
Comprehensive patient support services in the oncology setting are available through Sandoz One Source, a patient services center, which connects patients to the information and resources they need when they are taking Zarxio.
The launch follows the FDA approval of Zarxio on March 6, 2015. The approval, through the new biosimilars pathway established under the Biologics Price Competition and